# Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

> **NCT01866293** · PHASE1,PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 11 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Cabozantinib (XL184)

## Key facts

- **NCT ID:** NCT01866293
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-28
- **Primary completion:** 2016-08-18
- **Final completion:** 2016-08-18
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866293, "Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01866293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*